The basis of using immune checkpoint inhibitors such as PD-1 or PD-L1 blocking antibodies in cancer therapy is to enhance T cell-mediated antitumor immune responses and to generate functional tumor-specific CTLs capable of killing tumor cells [37, 38]. This evidence concerns the gene PDCD1 and cancer.